[Influence of DL-hydroxyproline on the development of experimental amyloidosis].
D000682:Amyloid / Q000096:biosynthesis; D000686:Amyloidosis / Q000378:metabolism* / Q000473:pathology; D000818:Animals; D002364:Caseins / Q000494:pharmacology; D003593:Cytoplasm / Q000032:analysis; D005260:Female; D006909:Hydroxyproline / Q000494:pharmacology*; D006965:Hyperplasia; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007674:Kidney Diseases / Q000473:pathology; D008099:Liver / Q000032:analysis; D008107:Liver Diseases / Q000473:pathology; D008206:Lymphatic Diseases / Q000473:pathology; D051379:Mice; D012157:Mononuclear Phagocyte System / Q000187:drug effects; D012313:RNA / Q000032:analysis; D013158:Splenic Diseases / Q000473:pathology
D000682:Amyloid; D002364:Caseins; D012313:RNA; D006909:Hydroxyproline
Uber den Einfluss des DL-Hydroxyprolins auf die Entwicklung der experimentellen Amyloidose.